| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | SPY072 (extended half-life investigational antibody targeting TL1A) rheumatoid arthritis (RA) | Phase 2 | — | Biologics | Musculoskeletal System | ||
phase 2 data readout example | SPY072 (extended half-life investigational antibody targeting TL1A) rheumatoid arthritis (RA) | Phase 2 | — | Biologics | Musculoskeletal System | ||
phase 2 data readout example | SPY072 (extended half-life investigational antibody targeting TL1A) rheumatoid arthritis (RA) | Phase 2 | — | Biologics | Musculoskeletal System |
Recent Updates
Recently added Catalysts
Spyre Therapeutics, Inc.$88.89
+0.11 (+0.12%)
C 49Pipeline Score Richly Valued Pharma · Commercial
Market Cap
6.43 B
EPS
-2.36
P/E Ratio
-
Value Trade
127.11 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
60.41 M
Operating CF
-57.37 M
Total Assets
763.95 M
Total Liabilities
93.14 M
Equity
670.81 M
D/E Ratio
12,345
-3.93 %
Week
1.49 %
1 Month
95.8 %
3 Month
217.95 %
6 Month
-60.03 %
5 Year
-70.38 %
All Time
Cash Data
Cash Position
741.47 M
Monthly Burn
19.12 M
Runway
37.1 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
1.68 M
52 Week Range
13.93 - 78.80
% held by Insiders
10.82 %
% held by Institutions
82.65 %
Enterprise Value
5.84 B
Total Shares
78.49 M
Short %
16.29 %
Float Shares
66.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Spyre Therapeutics, Inc.
459Total events
10Upcoming
95Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 10
2027
T1Topline Readout
Expected Part B induction data for monotherapies and combinations in SKYLINE-UC
Event history 449
Q3 2026
◆Topline ReadoutSPY003Clinical Data
Topline data expected for SPY003 Part A
ulcerative colitissource ↗
Q3 2026
◆Topline ReadoutSPY072Clinical Data
Topline proof-of-concept data for RA sub-study expected Q3 2026
rheumatoid arthritissource ↗
Jun 15, 2026
▲Primary Endpoint MetSPY002Clinical Data
SPY002 met primary endpoint with 10.7-point reduction in RHI at Week 12
moderate-to-severe ulcerative colitissource ↗
Jun 15, 2026
◆Full ResultsSPY002Clinical Data
Part A induction results announced for SPY002
moderate-to-severe ulcerative colitissource ↗
Jun 15, 2026
●Enrollment UpdateSPY002Trial
Part B enrollment ongoing for SKYLINE trial
moderate-to-severe ulcerative colitissource ↗
Jun 8, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 4, 2026
◆Oral PresentationSPY072Presentation
Preclinical data on TL1A inhibition in mouse models presented at EULAR 2026
rheumatic diseasessource ↗
Jun 3, 2026
Jun 3, 2026
▲Enrollment CompleteSPY072Trial
Enrollment completed for axSpA sub-study of SKYWAY basket trial
axial spondyloarthritissource ↗
Jun 2026
◆Topline ReadoutSPY002Clinical Data
Proof-of-concept induction data for SPY002 Part A expected mid-2026
moderate-to-severe ulcerative colitissource ↗
May 5, 2026
▲Enrollment CompleteSPY072Trial
Over-enrollment completed in RA sub-study of SKYWAY trial
rheumatoid arthritissource ↗
Drug Pipeline Intelligence
C49
Pipeline Score $736M
Pipeline ValueRichly Valued
Valuation Signal9
Drugs Scored0.1x
rNPV / MCap Top 75%
Small Cap (rank 227 of 905)
Percentile RankSpyre Therapeutics, Inc. carries a moderate pipeline score (49/100), with $1.1B risk-adjusted pipeline value, led by Pegzilarginase in Arginase I Deficiency (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pegzilarginase Small molecule | Arginase I Deficiency | Phase 3 | NCT03921541 | 55% | $260M | COMPLETED | 32 | - | - | Jan 27, 2023 | - | Nov 19, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SPY003 | — | Phase 1 | 2025-11-04 | |||
SPY003 | — | Phase 1 | 2025-11-04 | |||
SPY003 | — | Phase 1 | 2025-11-04 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SYRE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SYRE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SYRE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SYRESpyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients SPY002 met its primary endpoint with a statistically significant re
Spyre Therapeutics announced positive results from the Part A induction of the Phase 2 SKYLINE trial for SPY002, an anti-TL1A antibody. The results indicated a statistically significant 10.7-point reduction in the RHI score, along with notable rates of clinical remission (33%) and endoscopic improvement (42%). The drug's safety profile was deemed consistent with the TL1A class, although two serious adverse events were noted. Spyre is now enrolling Part B of the trial, which will evaluate multiple combination arms.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics has announced the approval of stock options as inducement awards to four non-executive employees. The grants, totaling 51,300 shares, are part of the company's 2018 Equity Inducement Plan and were crucial for the employees' acceptance of their roles. These stock options will vest over time, promoting long-term commitment to the company. This move reflects Spyre's focus on developing next-generation therapies in immunology.
Read more →SYRESpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
Spyre Therapeutics has completed enrollment for all sub-studies in the SKYWAY basket trial evaluating SPY072, an investigational therapy for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The company anticipates readouts for RA in Q3 2026 and for PsA and axSpA in Q4 2026. The swift enrollment reflects the significant unmet needs in the affected patient population and suggests potential enthusiasm for SPY072's advantages in treatment. Additionally, preclinical data supporting SPY072's efficacy in rheumatic diseases will be presented at the upcoming European Congress of Rheumatology.
Read more →SYRESpyre Therapeutics to Participate in Upcoming June Investor Conferences
Spyre Therapeutics, a biotechnology company focused on long-acting antibodies for inflammatory bowel disease and rheumatic diseases, announced its participation in two major investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference in New York and the Goldman Sachs Annual Global Healthcare Conference in Miami. Spyre's management will also hold one-on-one meetings with investors during these conferences, showcasing their commitment to investor relations and pipeline development.
Read more →SYRESpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics reported its first quarter 2026 financial results, highlighting positive topline data from the Phase 2 SKYLINE trial for SPY001, indicating potential best-in-class efficacy. The company has strengthened its financial position with $1.2 billion in cash and plans to accelerate readouts in its ongoing trials. The CEO expressed confidence in the pipeline's potential to redefine treatment standards for inflammatory bowel disease and rheumatic diseases.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards - May 1, 2026
Spyre Therapeutics has granted stock options to four non-executive employees as part of its 2018 Equity Inducement Plan. The options, totaling 20,800 shares, were approved on May 1, 2026, and are crucial for employee retention and recruitment. The exercise price is set at $69.42, aligning with the company's closing stock price on the same day.
Read more →SYRESpyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
Spyre Therapeutics, Inc. has successfully closed its public offering of 7,475,000 shares, raising approximately $463.5 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The proceeds will support Spyre's development of long-acting antibodies for inflammatory bowel disease and rheumatic diseases.
Read more →SYRESpyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
Spyre Therapeutics has announced the pricing of its public offering of 6.5 million shares at $62.00 each, aiming to raise approximately $403 million. The offering is expected to close on April 16, 2026, pending customary conditions. The company focuses on developing advanced treatments for Inflammatory Bowel Disease and other immune-mediated conditions.
Read more →SYRESpyre Therapeutics Announces Proposed Public Offering of its Common Stock - April 13, 2026
Spyre Therapeutics has announced a proposed public offering of $300 million in common stock, with an option for underwriters to purchase an additional $45 million. The offering is subject to market conditions and is being managed by several financial institutions. The company aims to use the proceeds to advance its pipeline focused on inflammatory bowel disease and other immune-mediated diseases.
Read more →SYRESpyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Spyre Therapeutics announced positive results from Part A of the Phase 2 SKYLINE trial for SPY001, showing a significant reduction in the RHI score for ulcerative colitis patients. The treatment was well tolerated, and recruitment for Part B is now open, which includes additional cohorts for monotherapy and combination therapies. The company anticipates further data releases in the coming years.
Read more →SYRESpyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics has announced a proposed public offering of $300 million in common stock to support its clinical-stage biotechnology initiatives. The offering includes an option for underwriters to purchase an additional $45 million. Market conditions may affect the offering's completion, and the company has filed a registration statement with the SEC. Spyre aims to develop advanced therapies for inflammatory bowel disease and other immune-mediated diseases.
Read more →SYRESpyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
Spyre Therapeutics will announce topline results from the SPY001 Part A induction of the SKYLINE trial for moderate-to-severe ulcerative colitis patients on April 13, 2026. Following the announcement, a conference call will be held to discuss the results. This trial is part of Spyre's efforts to redefine treatment standards for inflammatory bowel disease.
Read more →SYRESpyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
Spyre Therapeutics announced the completion of recruitment for its rheumatoid arthritis (RA) sub-study of the SKYWAY trial, with topline data now expected in Q3 2026. The study is focused on SPY072, a long-acting antibody that targets TL1A, and shows promise for treating inflammatory conditions. Along with expectations for positive data on other studies within the SKYWAY and SKYLINE programs, the company anticipates delivering key results quarterly throughout the year. This progress indicates a strong commitment to developing new treatments for rheumatic diseases.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards - March 6, 2026
Spyre Therapeutics has announced the grant of stock options to two non-executive employees as part of its 2018 Equity Inducement Plan. The options, totaling 46,600 shares, are intended to incentivize new hires and are set to vest over time. This move aligns with Spyre's strategy to enhance its workforce while focusing on long-acting antibodies for inflammatory bowel disease and rheumatic diseases.
Read more →SYRESpyre Therapeutics to Participate in Upcoming March 2026 Investor Conferences
Spyre Therapeutics, a clinical-stage biotechnology firm, announced its participation in several upcoming investor conferences in March 2026. The events include the TD Cowen 46th Annual Health Care Conference, the Leerink Global Healthcare Conference, and the Jefferies Biotech on the Beach Summit. Management will also hold one-on-one meetings with investors during these events.
Read more →SYRESpyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts f
Spyre Therapeutics has reported its fourth quarter and full year 2025 financial results, highlighting progress in its clinical trials. The company aims for six proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials, with enrollment proceeding ahead of schedule. Spyre's current financial position is robust, with $757 million available to support its pipeline into the second half of 2028. Additionally, the company has strengthened its leadership team with a new Chief Commercial Officer.
Read more →SYRESpyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
Spyre Therapeutics presented promising data on SPY003 at the 21st ECCO Congress. The Phase 1 study results indicated that SPY003 is well tolerated and may allow for less frequent dosing. Additionally, the company showcased its SKYLINE platform trial and preclinical findings that suggest dual targeting could enhance treatment efficacy for inflammatory bowel disease.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards - February 6, 2026
Spyre Therapeutics announced the grant of stock options to five non-executive employees as part of its 2018 Equity Inducement Plan. The options, totaling 30,200 shares, were approved on February 2, 2026, and are aimed at incentivizing new hires. The exercise price is set at $32.75, aligning with the company's stock price on that date.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards - January 23, 2026
Spyre Therapeutics announced the approval of stock options for Kate Chevlen, its new Chief Commercial Officer. The grant includes 108,155 shares with a 10-year term and an exercise price of $34.09. This inducement award is part of the company's strategy to attract top talent and is aligned with Nasdaq regulations.
Read more →SYRESpyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of- Concept Readouts Beginning in Q2 "6 in '26" expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial
Spyre Therapeutics is set for a pivotal year in 2026, with six expected proof-of-concept readouts from its SKYLINE and SKYWAY trial platforms. The trials aim to improve treatments related to ulcerative colitis and rheumatic diseases. Enrollment for SPY001 in the SKYLINE trial has been completed ahead of schedule, while the SKYWAY trial is on track. Moreover, the company's cash reserves of $783 million ensure operational stability into 2028, further strengthening its market position.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards - January 8, 2026
Spyre Therapeutics has announced the grant of stock options to six non-executive employees as part of its 2018 Equity Inducement Plan. The options, totaling 42,000 shares, were approved to incentivize new hires and come with a 10-year term and specific vesting conditions. This move aligns with Spyre's commitment to enhancing its workforce as it develops treatments for inflammatory bowel and rheumatic diseases.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards - December 5, 2025
Spyre Therapeutics has announced the approval of stock options as inducement awards for two non-executive employees. The options, totaling 20,300 shares, were granted under the 2018 Equity Inducement Plan, with a 10-year term and an exercise price of $28.66. This move is part of Spyre's strategy to attract talent in the competitive biotech sector.
Read more →SYRESpyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics announced its third quarter 2025 financial results, highlighting positive interim Phase 1 results for SPY003 and the initiation of the Phase 2 SKYWAY study for rheumatic diseases. The company reported a strengthened financial position with $316 million raised and is on track for six proof-of-concept readouts in 2026. However, it also noted a net loss of $11.2 million for the quarter.
Read more →SYRESpyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
Spyre Therapeutics announced positive interim results from its Phase 1 trial of SPY003, an extended half-life antibody targeting IL-23. The trial demonstrated that SPY003 was well tolerated, with an impressive half-life of approximately 85 days, suggesting potential for quarterly or biannual dosing. These results support the advancement of SPY003 into the SKYLINE Phase 2 trial, which aims to establish its efficacy in treating inflammatory bowel disease.
Read more →SYRESpyre Therapeutics to Participate in Upcoming November Investor Conferences
Spyre Therapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences in November 2025. These include the Guggenheim 2nd Annual Healthcare Innovation Conference, the Stifel 2025 Healthcare Conference, and the Jefferies Global Healthcare Conference. The company aims to showcase its pioneering work in long-acting antibodies for inflammatory bowel disease and rheumatic diseases.
Read more →SYRESpyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Spyre Therapeutics announced significant findings at the ACR Convergence 2025, showcasing follow-up data from their Phase 1 study of SPY072, an anti-TL1A agent for rheumatic diseases. The data indicate that SPY072 is well tolerated and supports extended dosing intervals. Additionally, preclinical results suggest its efficacy surpasses that of etanercept in treating collagen-induced arthritis.
Read more →SYRESpyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Spyre Therapeutics, Inc. has announced the successful closing of its public offering, raising approximately $316.2 million. The offering included 17,094,594 shares of common stock, with the underwriters exercising their option to purchase additional shares. This capital will support Spyre's development of next-generation therapies for Inflammatory Bowel Disease and other immune-mediated diseases.
Read more →SYRESpyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
Spyre Therapeutics has announced the pricing of its public offering of 14,864,865 shares at $18.50 each, aiming to raise approximately $275 million. The offering is expected to close around October 15, 2025, pending customary closing conditions. The company focuses on developing treatments for inflammatory bowel disease and other immune-mediated diseases.
Read more →SYRESpyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
Spyre Therapeutics has announced a proposed public offering of its common stock and pre-funded warrants. The offering is intended to support the company's efforts in developing treatments for Inflammatory Bowel Disease and other immune-mediated diseases. While the offering is subject to market conditions, it is backed by established underwriters, indicating potential investor confidence.
Read more →SYRESpyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
Spyre Therapeutics has announced presentations at the UEGW Congress, highlighting promising data from its Phase 1 study of SPY002, an anti-TL1A agent for IBD. The results indicate good tolerability and a potential for extended dosing intervals. Additionally, new preclinical data suggest that combination therapies outperform monotherapies in rodent models, supporting ongoing Phase 2 trials.
Read more →SYRESpyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
Spyre Therapeutics has initiated the first patient dosing in its Phase 2 SKYWAY trial for SPY072, an investigational anti-TL1A antibody aimed at treating various rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The trial will assess the antibody's efficacy and tolerability, with proof-of-concept results expected in 2026. SPY072 is designed to offer superior dosing convenience, potentially transforming treatment standards for patients who currently rely on more frequent therapies. The company anticipates delivering multiple data readouts from its ongoing trials in the coming years.
Read more →SYRESpyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
Spyre Therapeutics, a clinical-stage biotechnology company, will participate in the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025. Management will engage in a fireside chat and conduct investor meetings during the event. This participation reflects Spyre's commitment to advancing treatments for Inflammatory Bowel Disease and other immune-mediated diseases.
Read more →SYRESpyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, ex
Spyre Therapeutics announced its second-quarter 2025 financial results, highlighting positive interim results for two next-generation TL1A antibodies that were well-tolerated. The company is on track to initiate several Phase 2 trials, including the SKYLINE-UC and SKYWAY-RD studies, aimed at addressing ulcerative colitis and various rheumatic diseases. With a strong cash position of $526.6 million, Spyre is poised to advance its pipeline and generate numerous proof-of-concept readouts over the next two years.
Read more →SYRESpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
Spyre Therapeutics announced positive interim results for its Phase 1 trials of SPY002 and SPY072, two next-generation TL1A monoclonal antibodies. Both candidates were well tolerated and showed promising pharmacokinetics, supporting quarterly dosing. The company plans to advance these programs into Phase 2 trials, including the SKYLINE-UC and SKYWAY-RD studies, targeting ulcerative colitis and rheumatologic conditions.
Read more →SYRESpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
Spyre Therapeutics will announce interim results from its Phase 1 healthy volunteer trials for the SPY002 program on June 17, 2025. Following this announcement, the company will host a conference call and webcast to discuss the results. The SPY002 program focuses on developing novel half-life extended anti-TL1A antibodies for treating inflammatory bowel disease.
Read more →SYRESpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics reported its Q1 2025 financial results, highlighting progress in its clinical pipeline. The company is on track to initiate Phase 2 studies for ulcerative colitis and rheumatoid arthritis by mid-year. SPY001 and SPY002 are showing promising results, with interim data expected soon. Spyre maintains a strong financial position with $565 million in cash.
Read more →SYRESpyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
Spyre Therapeutics announced two poster presentations at Digestive Disease Week 2025, showcasing promising data for SPY001, a novel monoclonal antibody for treating Inflammatory Bowel Disease (IBD). The data indicates a potential best-in-class profile with a significantly extended half-life compared to existing therapies. The company plans to initiate a Phase 2 trial in mid-2025, focusing on ulcerative colitis.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a clinical-stage biotechnology company utilizing best-in-class antibody...
Spyre Therapeutics, Inc. announced the approval of stock options for seven non-executive employees as part of its equity inducement plan. A total of 64,400 shares can be purchased at an exercise price of $14.66, which reflects the company's closing stock price on May 1, 2025. The options will vest over time contingent on the employees' continued service with Spyre. This move aims to attract and retain talent as the company works on next-generation therapies for inflammatory bowel disease and other immune-mediated diseases.
Read more →SYRESpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
Spyre Therapeutics has initiated dosing in a Phase 1 trial for SPY003, a novel half-life extended IL-23 antibody. This trial aims to evaluate the safety and pharmacokinetics of SPY003 in healthy volunteers. Interim results are expected in the second half of 2025, with potential incorporation into a Phase 2 study for ulcerative colitis. The company aims to position SPY003 as a leading treatment option for inflammatory bowel disease.
Read more →SYRESpyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Reported positive interim pharmacokinetic ( PK ) and safety data in Phase 1 trial of SPY001 in November 2024 an
Spyre Therapeutics has reported its fourth quarter and full year 2024 financial results, highlighting positive interim data from the Phase 1 trial of SPY001. The company successfully raised $230 million, bolstering its cash position to $603 million, which supports its clinical pipeline. Looking ahead, Spyre plans to initiate Phase 2 trials for SPY001 in ulcerative colitis and SPY002 in rheumatoid arthritis by mid-2025. The CEO emphasized the potential of the portfolio to evolve treatment paradigms in inflammatory bowel disease and autoimmune conditions.
Read more →SYRESpyre Therapeutics to Participate in Upcoming March Investor Conferences Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and...
Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced its participation in two upcoming investor conferences, the TD Cowen 45th Annual Healthcare Conference and the Jefferies Biotech on the Beach Summit, scheduled for March 2025. These events will include interactive sessions such as a fireside chat and one-on-one meetings with investors. The company is advancing innovative treatments for Inflammatory Bowel Disease and other immune-mediated diseases, highlighting its commitment to developing next-generation therapies.
Read more →SYRESpyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a clinical-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics, Inc. announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation, showcasing preclinical findings for its SPY120 program. The research highlights that the combined inhibition of α4β7 integrin and TL1A cytokine outperforms monotherapy in mouse models of colitis. Additionally, the pharmacokinetic profiles of the SPY001 and SPY002 antibodies were consistent when dosed together, suggesting favorable dosing opportunities in humans. The company plans to initiate a Phase 2 trial for ulcerative colitis in mid-2025.
Read more →SYRESpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003,...
Spyre Therapeutics has outlined its 2025 priorities, expecting interim results from its pipelines, specifically SPY002 and SPY003, in 2025. The company plans to initiate a Phase 2 platform trial for ulcerative colitis and expand SPY002 into rheumatoid arthritis, with topline results anticipated in 2026. Spyre's strong cash reserves, exceeding $600 million, provide significant operational runway into the latter half of 2028. CEO Cameron Turtle highlighted the promising efficacy potential of their therapies compared to existing treatments in inflammatory bowel disease and RA.
Read more →SYRESpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim resu
Spyre Therapeutics has outlined its strategic priorities for 2025, focusing on promising upcoming clinical readouts. Key developments include Phase 1 interim result expectations for SPY002 and SPY003, both of which are extended half-life antibodies, and a Phase 2 trial in ulcerative colitis expected to begin in mid-2025. Additionally, the company plans to expand its SPY002 program into rheumatoid arthritis, with topline results anticipated in 2026. The company reported a strong cash position of over $600 million, ensuring operational continuity until at least the second half of 2028.
Read more →SYRESpyre Therapeutics Added to the Nasdaq Biotechnology Index Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic...
Spyre Therapeutics, Inc. has been included in the Nasdaq Biotechnology Index, which is designed to track the performance of biotechnology and pharmaceutical companies. Companies must meet specific eligibility criteria to be listed, reflecting their market capitalization and trading activity. This addition is significant for Spyre Therapeutics as it may lead to increased investor interest and market exposure. The Nasdaq Biotechnology Index is evaluated annually, indicating important milestones for companies within the sector.
Read more →SYRESPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Spyre Therapeutics, Inc. regarding potential violations of federal securities laws. The investigation stems from a recent disclosure by Spyre indicating that its previously issued financial statements should no longer be relied upon due to misapplication of accounting principles. This misstep has led to a finding of material weakness in the company's internal controls. Following these revelations, Spyre's stock price experienced a significant decline.
Read more →SYRESpyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies Preclinical data for both SPY002 molecules demonstrate picomolar...
Spyre Therapeutics has initiated the dosing of participants in Phase 1 trials for its novel anti-TL1A antibodies, SPY002-091 and SPY002-072, aimed at treating inflammatory and fibrotic diseases. The company has reported promising preclinical data demonstrating improved dosing convenience and potency compared to first-generation agents. Interim safety and pharmacodynamic data from these trials are expected in the second quarter of 2025, with aspirations to advance the candidates into Phase 2 studies thereafter. A strong financial position supports their ongoing development efforts, with over $630 million available from recent financing.
Read more →SYRESpyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic...
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is set to participate in the 7th Annual Evercore ISI HealthCONx Conference. The event underscores the company's commitment to showcasing its advancements in antibody engineering and rational therapeutic approaches. Interested parties can access the live webcast through the company's Investor section, with the replay available post-event. This participation highlights Spyre’s efforts to enhance its presence in the biotech community.
Read more →SYRESpyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants Spyre Therapeutics, Inc. ( Spyre or the Company ) (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody...
Spyre Therapeutics has announced a proposed public offering of its common stock and pre-funded warrants, with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C., and Guggenheim Securities, LLC acting as joint managers. While the offering has been registered with the SEC, its completion is uncertain and contingent on market conditions. The company has warned that forward-looking statements about the offering may not necessarily come to fruition due to various risks, including economic factors and industry competition.
Read more →SYRESpyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock Spyre Therapeutics, Inc. ( Spyre or the Company ) (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody...
Spyre Therapeutics has announced the pricing of a $200 million public offering of common stock. The offering, which involves prominent financial institutions like Jefferies and Goldman Sachs as managers, is set to close around November 20, 2024, pending customary conditions. A registration statement related to this offering has been filed with the SEC. This announcement comes during a period of economic instability and competitive pressures in the biotech sector.
Read more →SYRESpyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti- 4 7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of
Spyre Therapeutics announced positive interim results from its Phase 1 trial for SPY001, an investigational antibody for inflammatory bowel disease. The trial demonstrated that SPY001 was well-tolerated and showed a significant improvement in pharmacokinetics with a half-life of 90 days, allowing for potential less frequent dosing. The company plans to initiate a Phase 2 platform trial in mid-2025, focusing on further evaluation of SPY001's efficacy. These findings suggest SPY001 could become a key player in the treatment of inflammatory bowel disease.
Read more →SYRESpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a clinical-stage biotechnology company utilizing best-in-class antibody...
Spyre Therapeutics is set to host a conference call and webcast to discuss interim results from their Phase 1 healthy volunteer trial for SPY001, an innovative anti-α4β7 antibody designed to treat inflammatory bowel disease. The event will occur on November 12, 2024. The trial aims to evaluate the safety and effectiveness of this novel therapy. The company's investor relations page will provide access to the live and archived webcast.
Read more →SYRESpyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 20
Spyre Therapeutics has reported encouraging third quarter 2024 financial results and progress across their pipeline. The company's lead candidate, SPY001, is on track for interim Phase 1 data by the end of the year, while SPY002 is set to initiate first-in-human trials in Q4 2024. Additionally, preclinical data for SPY003 shows promising potential with a significantly extended half-life compared to competitors. With $414 million in cash, the company has a lengthy financial runway for continued development in inflammatory bowel disease treatments.
Read more →SYRESpyre Therapeutics to Participate in Upcoming November Investor Conferences Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic...
Spyre Therapeutics, Inc. (NASDAQ: SYRE) will participate in several upcoming investor conferences, showcasing its innovative approaches in biotechnology. The events include the Guggenheim's Inaugural Healthcare Innovation Conference on November 13, the Stifel 2024 Healthcare Conference on November 18, and the Jefferies London Healthcare Conference on November 20. Spyre intends to utilize these platforms to engage with investors and present their clinical-stage developments.
Read more →SYRESpyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre s Portfolio of Potentially Best-in-Class Antibodies and Combinations SPY003, a novel h
Spyre Therapeutics has announced an expected acceleration in the clinical timelines for its monoclonal antibody SPY003, now projected to begin first-in-human studies in the first quarter of 2025. The company presented new preclinical data supporting the drug's effectiveness, particularly its enhanced potency and extended half-life compared to risankizumab during the United European Gastroenterology Week. Spyre is positioning itself to develop advanced treatment options for inflammatory bowel disease (IBD) through its innovative antibody engineering and therapeutic combinations.
Read more →SYRESpyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a clinical-stage biotechnology company utilizing best-in-class antibody...
Spyre Therapeutics has appointed Dr. Sheldon Sloan as Chief Medical Officer, highlighting his notable previous roles, particularly in advancing therapies for inflammatory bowel disease. Dr. Sloan's appointment comes as Spyre aims to progress its promising antibody programs into clinical Phase 2 studies by 2025. The CEO emphasized Sloan's leadership as pivotal to scaling the medical organization necessary for the company’s ambitious roadmap. This strategic move is expected to strengthen Spyre's position in the biotechnology sector.
Read more →SYRESpyre Therapeutics to Participate in Upcoming Investor Conference Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic...
Spyre Therapeutics, Inc. (NASDAQ: SYRE) will participate in an upcoming investor conference, where they plan to showcase their advancements in antibody engineering and therapeutic development. A replay of the webcast will be accessible on their investor events website for 90 days after the event. The company's activities remain focused on progressive biotechnological innovations in the clinical stage. Details about the specific presentations or research updates at the conference have not been disclosed.
Read more →SYRESpyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Initiated dosing in Phase 1 trial of SPY001, an anti- 4 7 antibody engineered for infrequent, subcutaneous maintenance dosing
Spyre Therapeutics reported its financial results for the second quarter of 2024 and provided updates on its clinical development pipeline. The initiation of a Phase 1 trial for SPY001, an anti-4 7 antibody, marks a key step in the company's transition into a clinical-stage entity. With interim proof-of-concept data expected by the end of 2024 and a robust cash position of $426 million, the company is well-positioned for multiple future clinical readouts. Additionally, momentum is building with other programs, such as SPY002 and SPY003, which are advancing toward human trials.
Read more →SYRESpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or...
Spyre Therapeutics has announced the dosing of the first participants in a Phase 1 trial for its investigational drug SPY001, designed for the treatment of Inflammatory Bowel Disease (IBD). The trial aims to establish the safety and pharmacokinetics of the drug, which exhibits a potential dosing schedule every eight to twelve weeks, as opposed to the current standard of care. Additionally, the company expects to progress into Phase 2 development in 2025, depending on Phase 1 trial outcomes. Interim data from the ongoing Phase 1 trial is anticipated by year-end 2024, which could confirm the favorable safety profile of SPY001.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics, Inc. announced the grant of inducement awards in the form of stock options to its employees. These options come with a 10-year term and an exercise price set at $36.79, reflecting the stock's closing price as of June 3, 2024. The vesting schedule includes a significant time frame that connects employees' rewards to their continued service with the company. This strategic move is seen as a commitment to fostering talent within the organization.
Read more →SYRESpyre Therapeutics to Participate in the Jefferies Global Healthcare Conference Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics, a development-stage biotechnology company, is set to participate in the Jefferies Global Healthcare Conference. This involvement aims to enhance its visibility in the healthcare sector and showcase its advancements in antibody therapies. Following the conference, a webcast will be available for replay for 90 days, providing further accessibility to interested stakeholders.
Read more →SYRESpyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
Spyre Therapeutics has appointed Dr. Sandra Milligan to its Board of Directors, enhancing its leadership in the biopharmaceutical industry. Dr. Milligan, known for her extensive experience in clinical development, will play a pivotal role in guiding the company's innovative approaches to treating Inflammatory Bowel Disease (IBD). She succeeds Russell Cox, whose term ended recently. The company aims to advance its pipeline of antibody therapies, emphasizing improved efficacy and convenience over current treatments.
Read more →SYRESpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update SPY001, an anti- 4 7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity stud
Spyre Therapeutics has released its financial results for Q1 2024 and provided updates on its clinical pipeline, notably the progress of SPY001, which is set to begin first-in-human studies in Q2 2024. The company completed a successful 28-day GLP toxicity study for SPY001 and raised $180 million in financing to bolster its financial position. Spyre's cash reserves now amount to $485 million, with expectations that the runway extends well into 2027. Additionally, data from SPY001's Phase 1 trial is anticipated by the end of 2024, while first-in-human studies for SPY002 are planned for the latter half of 2024.
Read more →SYRESpyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics has announced a securities purchase agreement for a private investment in public equity (PIPE) financing, expected to raise approximately $180 million. The financing will help fund the company's pipeline of investigational antibody therapeutics aimed at transforming inflammatory bowel disease (IBD) treatments. With significant participation from both new and existing investors, Spyre anticipates that this injection of capital will extend its cash runway well into 2027. The deal is expected to close on March 20, 2024, pending customary closing conditions.
Read more →SYRESpyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Announced corporate name change to Spyre Therapeutics appointment of Cameron Turtle, DPhil, as Chief Executive
Spyre Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting a corporate name change and the appointment of Dr. Cameron Turtle as CEO. The company presented promising preclinical data on its investigational therapies SPY001 and SPY002, with plans to initiate first-in-human studies in 2024. Additionally, Spyre raised $180 million in recent financing, positioning it for future developments in treatment options for inflammatory bowel disease. The company aims to enter multiple clinical studies while managing a strong cash position to support its operations through 2026.
Read more →SYRESpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics, a development-stage biotechnology company, will participate in the 44th Annual TD Cowen Health Care Conference on March 5, 2024. CEO Cameron Turtle will be part of a panel discussion focusing on Inflammation & Immunology. The event offers a platform for Spyre to present its advancements in antibody development. Additionally, a webcast will be available for public access following the conference.
Read more →SYRESpyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics announced that three abstracts related to their lead programs SPY001 and SPY002 have been accepted for presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation. The abstracts showcase promising preclinical findings demonstrating the potency and selectivity of these investigational antibodies, along with an observed extended half-life in animal models. If confirmed in clinical trials, these properties could enable less frequent dosing of the therapies. The company plans to initiate Phase 1 clinical studies for both programs within the year.
Read more →SYRESpyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics has appointed Mark C. McKenna, former CEO of Prometheus Biosciences, to its Board of Directors. This appointment aims to leverage McKenna's extensive experience in the biopharma sector, with a particular focus on improving treatment options for inflammatory bowel disease (IBD). In 2023, Spyre raised $390 million, enabling the company to advance its pipeline candidates into clinical stages. Notably, McKenna's insight is anticipated to guide the development of new therapies in both monotherapy and combination treatment formats. Additionally, Alison Lawton will resign from the board effective February 1, 2024.
Read more →SYRESpyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics, Inc. ( Spyre ) (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...
Spyre Therapeutics, Inc. announced that its independent Compensation Committee approved the grant of 411,000 stock options to three non-executive employees as part of equity inducement awards. This decision is aligned with the Nasdaq Listing Rule and was made on December 18, 2023. The options come with a 10-year term and an exercise price equal to Spyre's common stock closing price on that date, aiming to attract talent to support its pipeline of antibody therapeutics.
Read more →SYRESpyre Therapeutics to Present at Upcoming Investor Conference Spyre Therapeutics, Inc. ( Spyre ) (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a biotechnology firm, announced that its CEO, Cameron Turtle, will present at an upcoming investor conference. The company focuses on developing antibody therapeutics aimed at transforming treatments for inflammatory bowel disease (IBD). The conference's webcast will be accessible on the Spyre website, with a replay available for 90 days post-event. This participation reflects Spyre's commitment to engaging with its investment community.
Read more →SYREAeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD Company
Aeglea BioTherapeutics has announced its rebranding to Spyre Therapeutics, effective from November 28, 2023, as it aims to advance the development of next-generation therapies for inflammatory bowel disease (IBD). The company has appointed Cameron Turtle as CEO and expanded its leadership team with industry veterans Jeffrey Albers and Laurie Stelzer. Spyre has a strong financial position with $205 million to support its operational goals, and is set to initiate clinical studies for its lead candidates in 2024. The company seeks to combine best-in-class antibody engineering with rational therapeutic strategies to improve patient outcomes in IBD.
Read more →SYREITEM 7. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our f
Aeglea BioTherapeutics is a clinical-stage biotechnology company focused on developing enzyme therapeutics for rare metabolic diseases. They are advancing two key clinical programs: pegtarviliase for Classical Homocystinuria and pegzilarginase for Arginase 1 Deficiency. Despite recent positive topline data for pegzilarginase, the FDA has requested additional data for its Biologics License Application. Overall, the company is facing financial challenges, with significant net losses and doubts about its future viability.
Read more →SYREAeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a hal
Aeglea BioTherapeutics reported its Q3 2023 financial results and highlighted progress in its inflammatory bowel disease (IBD) portfolio. The company is preparing for IND filings for two antibody therapies, SPY001 and SPY002, with first-in-human studies expected in 2024. They reported a strong cash position of $204.9 million but also a notable net loss of $40.1 million. Additionally, Aeglea strengthened its leadership team and scheduled a shareholder vote for preferred stock conversion.
Read more →SYRECORPORATE OVERVIEW 24 October 2023 Disclosures The information contained in this presentation has been prepared by Aeglea Biotherapeutics, Inc. and its affiliates, including Spyre Therapeutics, Inc. ("Spyre" or the "Comp
Aeglea Biotherapeutics, Inc. and its affiliate Spyre Therapeutics have outlined their business operations and strategies, focusing on their approach to developing therapies for inflammatory bowel disease (IBD). They aim to address substantial unmet needs in IBD management through innovative approaches, including the development of long-acting antibodies and targeted therapies. The company anticipates the release of Phase 1 interim data for several of its promising lead candidates by the end of 2024 and into 2025.
Read more →SYREReport of Independent Registered Public Accounting Firm To the Board of Directors of Aeglea BioTherapeutics, Inc. Opinion We have audited the accompanying statement of assets acquired and liabilities assumed from Spyre T
Aeglea BioTherapeutics has released an independent auditor's report concerning its acquisition of assets from Spyre Therapeutics as of June 22, 2023. The audit found that the financial statement accurately reflects the assets acquired and liabilities assumed, but raised significant concerns regarding Aeglea's ability to remain a going concern due to its financial obligations. Notably, the liabilities assumed from Spyre greatly outstrip the assets acquired, leading to a net liability of $17,012. The report serves as a crucial document in understanding Aeglea's financial health post-acquisition.
Read more →SYREDisclosures The information contained in this presentation has been prepared by Aeglea Biotherapeutics, Inc. and its affiliates, including Spyre Therapeutics, Inc. ("Spyre" or the "Company") and contains information pert
Aeglea Biotherapeutics, Inc. has completed the acquisition of Spyre Therapeutics, marking a strategic enhancement to its business operations. The acquisition was structured as a stock-for-stock transaction, financed concurrently with a private placement that raised $210 million. These funds are intended to support the development of Spyre's pipeline, with key milestones set for upcoming clinical trials and regulatory submissions. The move positions Aeglea to take advantage of growth opportunities in the inflammatory bowel disease market, which is valued at $21 billion.
Read more →SYREAeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones Scott Burrows, former Arcutis Biotherapeutics CFO, assumes role as Chief Financial O
Aeglea BioTherapeutics has appointed Scott Burrows as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary, enhancing its leadership team with experienced professionals from the biopharma industry. Burrows previously served at Arcutis Biotherapeutics, while King-Jones was at Provention Bio, where she contributed to multiple successful transitions. These appointments aim to strengthen financial and corporate governance as Aeglea progresses with its pipeline of therapies for inflammatory bowel disease (IBD). Jonathan Alspaugh will transition to a strategic advisory role through the end of 2023.
Read more →SYREAeglea BioTherapeutics Reports Second Quarter 2023 Financial Results Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-cl
Aeglea BioTherapeutics reported its second quarter 2023 financial results, highlighting the successful acquisition of Spyre Therapeutics and a concurrent $210 million private investment. This positions Aeglea to enhance its portfolio focused on inflammatory bowel disease (IBD), with plans to initiate clinical trials for its antibody candidates SPY001 and SPY002 in 2024. However, the company also reported a substantial net loss of $217.1 million for the quarter, largely influenced by acquisition expenses and increased operating costs. The company's strategic shift towards IBD signifies its commitment to developing new treatments for chronic diseases.
Read more →SYREAeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to
Aeglea BioTherapeutics has sold the global rights to pegzilarginase, an investigational treatment for Arginase 1 Deficiency (ARG1-D), to Immedica Pharma for $15 million upfront and the potential for up to $100 million in contingent milestone payments. The agreement supersedes a previous license between the two companies. The marketing authorisation application for pegzilarginase is currently under review by the European Medicines Agency, while Immedica is set to continue discussions with the FDA for U.S. advancement of the therapy. This move aligns with Aeglea's strategic shift towards inflammatory bowel disease (IBD).
Read more →SYREDisclosures The information contained in this presentation has been prepared by Spyre Therapeutics, Inc. and its affiliates ("Spyre" or the "Company") and contains information pertaining to the business and operations of
Spyre Therapeutics, Inc. has presented an overview of its recent acquisition structured as a stock-for-stock transaction. Concurrently, the company secured $210 million in financing from institutional investors, indicating strong market confidence. Proceeds will primarily focus on advancing Spyre's pipeline, with two Investigational New Drug applications anticipated in 2024. The presentation also highlights the potential for best-in-class therapies targeting inflammatory bowel disease.
Read more →SYREAeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics Acquisition of Spyre and concurrent oversubscribed $210M private investment positions the company to advance a leading inflammatory bowel disease (IBD) p
Aeglea BioTherapeutics has announced the acquisition of Spyre Therapeutics, enhancing its position in the inflammatory bowel disease (IBD) market. The acquisition, coupled with an oversubscribed private investment of $210 million, aims to support the advancement of Spyre's promising pipeline of antibody therapeutics. With these resources, Aeglea intends to fund operations through 2026 and accelerate the development of potentially best-in-class treatments targeted for patients suffering from IBD. Spyre's lead programs are expected to enter clinical trials in 2024, aiming to address unmet needs in IBD management.
Read more →SYREAeglea BioTherapeutics Reports First Quarter 2023 Financial Results $39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of
Aeglea BioTherapeutics reported its financial results for the first quarter of 2023, indicating available cash and cash equivalents of $39.8 million. The company's revenues from development fees and royalties stood at $0.2 million, a significant drop from $1.4 million year-over-year. Operating expenses decreased, with net loss reported at $18.4 million, down from $24.4 million in the previous year's quarter. Aeglea's drug pegzilarginase met its primary endpoint in the PEACE Phase 3 trial, and its Marketing Authorization Application is under review by the European Medicines Agency.
Read more →SYREForward Looking Statements 2023 Aeglea BioTherapeutics This presentation by Aeglea BioTherapeutics, Inc. ("we", "our" or "us") contains "forward-looking" statements within the meaning of the Private Securities Litigation
Aeglea BioTherapeutics has released a corporate overview highlighting their forward-looking statements regarding financial performance and strategic plans. The company is currently reviewing interim results for their product candidates Pegtarviliase and Pegzilarginase, with the latter's MAA awaiting a potential approval decision later this year. However, challenges such as anti-drug antibodies affecting trial data and announced workforce reductions may impact their operations. The company also reported a preliminary cash estimate of approximately $39.8 million as of March 31, 2023, which will play a crucial role in funding future developments.
Read more →SYREAeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives Results from Coho
Aeglea BioTherapeutics announced interim results from the Phase 1/2 trial of pegtarviliase, showing promise in reducing homocysteine levels for Classical Homocystinuria. However, inconsistent results in the highest dosage cohort suggest further exploration is needed. The company is also looking into strategic alternatives, including a potential acquisition or merger, while reducing its workforce. Current efforts to address the drug's efficacy and ongoing clinical programs continue amidst these changes.
Read more →SYREAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates Jeffrey Goldberg, experienced biotech executive, appointed president and CEO; further strengthened senior ma
Aeglea BioTherapeutics announced its financial results for Q4 and full year 2022, reporting a net loss of $18.8 million for the fourth quarter, down from $20.4 million in Q4 2021. The company highlighted significant leadership changes, including the appointment of Jeffrey Goldberg as the new CEO and the advancement of clinical trials for its therapies, pegtarviliase and pegzilarginase. Aeglea has $57.3 million in available cash, expected to fund operations into Q4 2023. The company has received Fast Track Designation for pegtarviliase and continues to progress towards potential EMA approval for pegzilarginase.
Read more →SYREForward Looking Statements 2023 Aeglea BioTherapeutics This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on infor
Aeglea BioTherapeutics presented forward-looking statements addressing their innovative therapies for rare diseases. The company highlighted the ongoing clinical trials for pegzilarginase and pegtarviliase, alongside financial projections and anticipated regulatory approvals. Challenges such as regulatory hurdles and the impact of the COVID-19 pandemic on clinical trials were acknowledged. The company's leadership transition may influence future developments and market strategies.
Read more →SYREAeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 a
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kg MAA for Pegzilarginase for the Treatment of A
Read more →SYREReimagining The Potential Of Human Enzyme Therapeutics Corporate Overview - September 2022 Nasdaq: AGLE Forward Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statem
Corporate Overview - September 2022 Nasdaq: AGLE Forward Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to managem
Read more →SYREAeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Id
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forward for Pegzilarginase Gross P
Read more →SYREAeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional PEACE data supporting potential e
Read more →SYREAeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD Austin, Texas
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD Austin, Texas, April 11, 2022 - Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new gener
Read more →SYREAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates Pegzilarginase BLA preparation on track to enable a second quarter 2022 submission to the FDA Accelerating P
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates Pegzilarginase BLA preparation on track to enable a second quarter 2022 submission to the FDA Accelerating Phase 1/2 trial of AGLE-177 for Homocystinuria; clinical da
Read more →SYREForward Looking Statements 2022 Aeglea BioTherapeutics. External 2 This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions
Reimagining The Potential Of Human Enzyme Therapeutics Corporate Overview - January 2022 Nasdaq: AGLE Exhibit 99.1 Forward Looking Statements 2022 Aeglea BioTherapeutics. External 2 This presentation and the accompanying oral presentation contain "forward-looking" statements tha
Read more →SYREAeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency 80% plasma arginine reduction (primary endpoint; p 0.0001) accompanied by a posit
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency 80% plasma arginine reduction (primary endpoint; p < 0.0001) accompanied by a positive trend in GMFM-E, a key clinical assessment of patient
Read more →SYREAeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights PEACE baseline data at upcoming medical meeting underscore disease severity and significant limitations of current standard of
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights PEACE baseline data at upcoming medical meeting underscore disease severity and significant limitations of current standard of care in controlling plasma arginine levels Topline safety
Read more →SYRECompany Logo Forward Looking Statements 2021 Aeglea BioTherapeutics. External 2 This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and
Reimagining The Potential Of Human Enzyme Therapeutics Corporate Overview - September 2021 Exhibit 99.1 Company Logo Forward Looking Statements 2021 Aeglea BioTherapeutics. External 2 This presentation and the accompanying oral presentation contain "forward-looking" statements t
Read more →SYREAeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights Initiated Dosing in Phase 1/2 Clinical Trial of AGLE-177 in Homocystinuria Strengthened Leadership Team with Key Appointments,
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights Initiated Dosing in Phase 1/2 Clinical Trial of AGLE-177 in Homocystinuria Strengthened Leadership Team with Key Appointments, Including Jonathan Alspaugh as Chief Financial Officer A
Read more →SYREAeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights Completed Patient Randomization for Phase 3 PEACE Clinical Trial; Topline Data Expected in Q4 Entered into Ex-U.S. Commercializ
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights Completed Patient Randomization for Phase 3 PEACE Clinical Trial; Topline Data Expected in Q4 Entered into Ex-U.S. Commercialization Agreement for Pegzilarginase with Upfront and Miles
Read more →SYREAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Phase 3 PEACE Study Enrollment Expected to Complete in March; Topline Data Expected in Fourth Quarter Received U
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Phase 3 PEACE Study Enrollment Expected to Complete in March; Topline Data Expected in Fourth Quarter Received U.S. Rare Pediatric Disease Designation for AGLE-177 for th
Read more →SYREForward Looking Statements 2020 Aeglea BioTherapeutics. External 2 This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions
Reimagining The Potential Of Human Enzyme Therapeutics Corporate Overview - January 2021 Exhibit 99.1 Forward Looking Statements 2020 Aeglea BioTherapeutics. External 2 This presentation and the accompanying oral presentation contain "forward-looking" statements that are based o
Read more →SYREAeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177 Continued Progress in Arginase 1 De
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177 Continued Progress in Arginase 1 Deficiency Patient Identification and Engagement Efforts Au
Read more →SYREAeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Op
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension Study Initiated Phase 1/2 Clinical Tri
Read more →SYREAeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6 th Congress of the European Academy of Neurology Pegzilarginase Showed Durable Clinical Response at 56 Week
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained R
Read more →SYREAeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for ACN00177 Approved by MHRA; Progress Toward Phase 1/2 Clini
Read more →SYREForward Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available t
Aeglea Corporate Overview Exhibit 99.1 Forward Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forwar
Read more →SYREAeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Qu
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Quarter of 2020, with Topline Data Expected in First Quarter
Read more →SYREAeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177) Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177) Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020 AUSTIN, Texas, January 13, 2020 -- Aeglea BioTherapeutics, Inc. (NASDAQ:A
Read more →SYREAeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights Austin, Texas
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights Austin, Texas, November 6, 2019 - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for
Read more →SYREAeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79% Management to Host Conferen
Read more →SYREAeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in Global Pivotal Phase 3 PEACE Trial New Data from Arginase
Read more →SYREAeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Mill
Read more →SYREAeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders Consistent, Marked, and Susta
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders Consistent, Marked, and Sustained Lowering of Elevated Plasma Arginine with Pegzilargina
Read more →SYREAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with
Read more →SYREAeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency Single, Global Pivotal Trial to Support Registration; Primary Endpoint of Arginine Reduction Expec
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency Single, Global Pivotal Trial to Support Registration; Primary Endpoint of Arginine Reduction Expected to Initiate in Q2 2019; Topline Data Anticipated in Q1
Read more →SYREAeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Austin, Texas
Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Austin, Texas, November 8, 2018 - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics
Read more →SYREAeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress Pegzilarginase Monotherapy Demonstrates Anti-Tum
Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress Pegzilarginase Monotherapy Demonstrates Anti-Tumor Activity Austin, Texas, October 22, 2018 - Aeglea BioTh
Read more →SYREAeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency Pegzilarginase is Effect
Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency Pegzilarginase is Effective in Sustainably Lowering Plasma Arginine Levels Clinica
Read more →SYREAeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency Exceeded Enrollment Target with 15 Patient
Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency Exceeded Enrollment Target with 15 Patients in Phase 1/2 Trial Additional Interim Data to be Present
Read more →SYREAeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results Austin, Texas
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results Austin, Texas, August 9, 2018 - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics fo
Read more →SYREAeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results Austin, Texas
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results Austin, Texas, May 8, 2018 - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for pa
Read more →SYREAeglea BioTherapeutics Prices Public Offering of Common Stock
Aeglea BioTherapeutics Prices Public Offering of Common Stock AUSTIN, Texas, April 18, 2018 Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases
Read more →SYREAeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting Clinical Outcome Assessment
Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting Clinical Outcome Assessment Tools Detected and Quantified Baseline Abnormalities Clin
Read more →SYREAeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results Repeat Doses of Company's Pegzilarginase Produces Marked and Sust
Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results Repeat Doses of Company's Pegzilarginase Produces Marked and Sustained Reductions in Plasma Arginine Levels Accompanying R
Read more →SYREAeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results Austin, Texas
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results Austin, Texas, November 7, 2017 - Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid m
Read more →SYREAeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results Austin, Texas
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results Austin, Texas, August 9, 2017 - Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid me
Read more →SYRERESIGNATION LETTER
Aeglea BioTherapeutics, Inc. To the Board of Directors: Effective as of the date written above, I hereby voluntarily resign (i) as a member of the Board of Directors (the Board ) of Aeglea BioTherapeutics, Inc. (together with its subsidiaries, the Company ) and as a member of
Read more →SYREAeglea BioTherapeutics Prices Public Offering of Common Stock Austin, Texas (
Aeglea BioTherapeutics Prices Public Offering of Common Stock Austin, Texas (June 6, 2017) Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases
Read more →SYREAeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results Austin, Texas
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results Austin, Texas, May 9, 2017 - Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabo
Read more →SYREAeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results -- Topline Results Presented Today of Phase 1 Open-Label Study of AEB1102 Enzyme Replacement Therapy in Adu
Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results -- Topline Results Presented Today of Phase 1 Open-Label Study of AEB1102 Enzyme Replacement Therapy in Adult Patients with Arginase I Deficiency -- -- Conference Ca
Read more →SYREAeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results Austin, Texas
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results Austin, Texas, November 9, 2016 - Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid m
Read more →SYREAeglea BioTherapeutics Announces Second Quarter 2016 Financial Results Austin, Texas
Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results Austin, Texas, August 9, 2016 - Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare disea
Read more →SYREAeglea BioTherapeutics Announces First Quarter 2016 Financial Results Austin, Texas
Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results Austin, Texas, May 19, 2016 - Aeglea BioTherapeutics, Inc., (NASDAQ: AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors
Read more →SYRETargeting Chronic Lymphocytic Leukemia by Interfering Glutathione Synthesis Using a Novel Therapeutic Enzyme Cyst(e)inase (AEB3103) Abstract Number: 3073 Jinyun Liu1, Li Feng1, Everett M. Stone2, Joseph Tyler3, Scott W.
Targeting Chronic Lymphocytic Leukemia by Interfering Glutathione Synthesis Using a Novel Therapeutic Enzyme Cyst(e)inase (AEB3103) Abstract Number: 3073 Jinyun Liu1, Li Feng1, Everett M. Stone2, Joseph Tyler3, Scott W. Rowlinson3, Michael J. Keating4, Peng Huang1 1 , , , 2Depar
Read more →SYREAbstract # 1042 Development of AEB1102, an Engineered Human Arginase 1 for Patients with Solid Tumors S W Rowlinson, S E Alters, G Agnello, J Tyler, A Lowe, M Okamoto-Kearney, D Johnson, E M Stone*, G Georgiou*, and D G
Development of AEB1102, an Engineered Human Arginase 1 for Patients with Solid Tumors S W Rowlinson, S E Alters, G Agnello, J Tyler, A Lowe, M Okamoto-Kearney, D Johnson, E M Stone*, G Georgiou*, and D G Lowe Aeglea Biotherapeutics 901 S MO PAC EXPY, Barton Oaks Plaza One, Suit
Read more →Competitive Position
How SYRE ranks across every disease it competes inCompetitive Position is a premium feature
See how SYRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial